Results 111 to 120 of about 338,657 (254)

A disease model predicting placebo response and remission status of patients with ulcerative colitis using modified Mayo score. [PDF]

Clin Transl Sci, 2023
Moein A, Langenhorst J, Plan EL, Jin JY, Kågedal M, Kassir N.   +5 more
europepmc   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Placebo Response in Trials of Negative Symptoms in Schizophrenia: A Critical Reassessment of the Evidence. [PDF]

Schizophr Bull, 2022
Czobor P, Kakuszi B, Bitter I.
europepmc   +1 more source

Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double‐Blind, Phase 3 POETYK PsA‐2 Trial

Arthritis &Rheumatology, Accepted Article.
Objective To assess the efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with psoriatic arthritis (PsA) who were naive to biologic disease‐modifying antirheumatic drugs or received tumor necrosis factor inhibitors. Methods In the 52‐week (W), double‐blind, placebo‐controlled, phase 3 POETYK PsA‐2 study
Philip J. Mease, Vinod Chandran, April W. Armstrong, Ricardo Blanco, Alexis Ogdie, Evan L. Siegel, Alice B. Gottlieb, Xiaofeng Zeng, Diamant Thaçi, Mitsumasa Kishimoto, Hendrik Schulze‐Koops, Alan Kivitz, Eva Dokoupilová, Akimichi Morita, Eric M. Ruderman, Michael Plewinski, Kejia Wang, Caroline Sardinas, Eleni Vritzali, John Vaile, Atul Deodhar   +20 more
wiley   +1 more source

Outcomes in progressive pulmonary fibrosis in systemic autoimmune rheumatic diseases: real‐world data from the ILD‐PRO Registry

Arthritis &Rheumatology, Accepted Article.
Objective We evaluated baseline characteristics, treatment patterns, and outcomes in patients with systemic autoimmune rheumatic disease‐associated progressive pulmonary fibrosis (SARD‐PPF) and evaluated whether outcomes differed by SARD subtype. Methods The ILD‐PRO Registry is a prospective multicenter US registry of patients with PPF.
Sonali J Bracken, Jeremy M Weber, Megan L Neely, Aparna C Swaminathan, Scott M Palmer, Erin M Wilfong, Ann D Chauffe, Elizabeth R Volkmann   +7 more
wiley   +1 more source

Interpreting clinical trial outcomes complicated by placebo response with an assessment of false-negative and true-negative clinical trials in depression using propensity-weighting. [PDF]

Transl Psychiatry, 2023
Gomeni R, Hopkins S, Bressolle-Gomeni F, Fava M.   +3 more
europepmc   +1 more source

Task‐Related Aperiodic EEG (1/f) Activity in Autism

Autism Research, EarlyView.
ABSTRACT Autism has been hypothesized to involve atypicalities in the balance between neural excitation and inhibition (E/I). Aperiodic EEG activity, characterized by the 1/f exponent of the power spectrum, provides a proxy of cortical E/I dynamics. However, prior studies in autism report mixed findings regarding the slope of aperiodic activity.
Magdalena Matyjek, Salvador Soto Faraco, Claudia Alvarez Martin, Mireia Torralba Cuello   +3 more
wiley   +1 more source

Predictive biomarkers of placebo response in patients with cancer: an exploratory analysis of the ABCD randomized clinical trial. [PDF]

Support Care Cancer
Hui D, Jennings K, Ontai A, Hanneman SK, Bruera E.   +4 more
europepmc   +1 more source

Interaction of the Gut Microbiota and the Enteric Nervous System: Implications in Gastrointestinal Disorders Associated With Autism Spectrum Disorder

Autism Research, EarlyView.
ABSTRACT Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impairments in social interaction, restricted interests, and repetitive behaviors. In addition to these core behavioral symptoms, gastrointestinal (GI) disorders are frequently reported, ranging from severe constipation to diarrhea.
Baptiste Ganachaud, María José Mendoza‐León, Justine Marchix, Alonso Fernandez Tello, Catherine Le Berre Scoul, Ma Cecilia Opazo, Michel Neunlist, Claudia A. Riedel, Martial Caillaud, Hélène Boudin   +9 more
wiley   +1 more source

Domain Specific Placebo Response in the Modified Friedreich's Ataxia Rating Scale. [PDF]

Ann Clin Transl Neurol
Rummey C, Farmer JM, Lynch DR.
europepmc   +1 more source